BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 23249906)

  • 1. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Pediatr Infect Dis J; 2013 Jun; 32(6):656-61. PubMed ID: 23249906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Clin Vaccine Immunol; 2013 Oct; 20(10):1524-30. PubMed ID: 23925887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Giangaspro E; Del Castillo F; Hernández-Sampelayo T; Otheo E; Balboa F; Ríos E; Méndez C;
    Clin Vaccine Immunol; 2011 Jan; 18(1):89-94. PubMed ID: 21047996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccines.
    Picazo J; Dueñas J; Ramirez A; Perez AR; Padilla E; Herrero S; Gallegos C; Culebras E; Balseiro C; Mendez C
    BMC Infect Dis; 2013 Oct; 13():503. PubMed ID: 24498901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
    Kaplan SL; Barson WJ; Lin PL; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatr Infect Dis J; 2013 Mar; 32(3):203-7. PubMed ID: 23558320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the different 13-valent pneumococcal conjugate vaccination uptakes on the invasive pneumococcal disease in children: Analysis of a hospital-based and population-based surveillance study in Madrid, Spain, 2007-2015.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; Baquero F; Hernández-Sampelayo T; Otheo E; Méndez C;
    PLoS One; 2017; 12(2):e0172222. PubMed ID: 28207888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.
    Myint TT; Madhava H; Balmer P; Christopoulou D; Attal S; Menegas D; Sprenger R; Bonnet E
    Adv Ther; 2013 Feb; 30(2):127-51. PubMed ID: 23397399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease.
    Ben-Shimol S; Greenberg D; Hazan G; Givon-Lavi N; Gottesman G; Grisaru-Soen G; Dagan R;
    Pediatr Infect Dis J; 2015 Apr; 34(4):409-16. PubMed ID: 25764098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
    Moore MR; Link-Gelles R; Schaffner W; Lynfield R; Lexau C; Bennett NM; Petit S; Zansky SM; Harrison LH; Reingold A; Miller L; Scherzinger K; Thomas A; Farley MM; Zell ER; Taylor TH; Pondo T; Rodgers L; McGee L; Beall B; Jorgensen JH; Whitney CG
    Lancet Infect Dis; 2015 Mar; 15(3):301-9. PubMed ID: 25656600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Elias N; Glikman D; Rubinstein U; Dagan R;
    Vaccine; 2012 Oct; 30(46):6600-7. PubMed ID: 22939907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W; Liu Z; Shigayeva A; Low DE; Green K; Plevneshi A; Devlin R; Downey J; Katz K; Kitai I; Krajden S; Ostrowska K; Richardson D; Richardson S; Sarabia A; Silverman M; Simor AE; Tyrrell G; McGeer A;
    Vaccine; 2013 Dec; 31(49):5863-71. PubMed ID: 24099873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.
    van der Linden M; Weiß S; Falkenhorst G; Siedler A; Imöhl M; von Kries R
    Vaccine; 2012 Aug; 30(40):5880-5. PubMed ID: 22771186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.